TY - JOUR T1 - Measurement properties of the minimal disease activity criteria for psoriatic arthritis JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2019-001002 VL - 5 IS - 2 SP - e001002 AU - Laura C Coates AU - Vibeke Strand AU - Hilary Wilson AU - Dennis Revicki AU - Brad Stolshek AU - Ahmed Samad AU - James B Chung AU - Dafna Gladman AU - Philip J Mease Y1 - 2019/09/01 UR - http://rmdopen.bmj.com/content/5/2/e001002.abstract N2 - Objective To comprehensively assess evidence on the measurement properties of the minimal disease activity (MDA) criteria, a composite measure of the state of disease activity in psoriatic arthritis (PsA).Methods A targeted literature review was conducted to identify studies that informed the validity and/or ability of the MDA to detect change among patients known to have experienced a change in clinical status. The search was conducted using MEDLINE and Embase databases (published as of October 2017). Pertinent articles provided by investigators and identified from select conference proceedings were also evaluated.Results A total of 20 publications met the inclusion criteria. The MDA criteria were consistently associated with other indicators of disease activity/severity. The ability of the MDA criteria to detect change was supported in randomised controlled trials (n=10), with a greater percentage of patients randomised to active treatments achieving MDA relative to patients in comparator arms. Long-term observational studies (n=2) provided additional support for the ability of the MDA to detect within-subject change in the real-world settings.Conclusion Evidence supports the MDA as a valid measure of disease activity in PsA that can detect between-group and within-subject change. The MDA is a comprehensive measure and clinically meaningful endpoint to assess the impact of interventions on PsA disease activity. ER -